Abpro Holdings, Inc Common Stock
About: Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
63% more funds holding
Funds holding: 8 [Q3] → 13 (+5) [Q4]
0.08% less ownership
Funds ownership: 3.14% [Q3] → 3.06% (-0.08%) [Q4]
21% less capital invested
Capital invested by funds: $2.53M [Q3] → $1.99M (-$534K) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Jason McCarthy 14% 1-year accuracy 5 / 35 met price target | 1,076%upside $4 | Buy Initiated | 24 Feb 2025 |
Financial journalist opinion


